Abstract
The cost effectiveness of labetalol and propranolol in the treatment of black adults with mild to moderate hypertension was assessed using published reports from US clinical trials of these agents among such patients. Data from these studies suggest that labetalol and propranolol lower diastolic blood pressure among black hypertensive adults by 11.2 mmHg and 8.4 mmHg, respectively. Results indicate that, for a hypothetical cohort of 1,000 patients on monotherapy, patients treated with labetalol would experience two to seven fewer strokes over a ten-year period, depending upon age and sex, and annual drug costs would be reduced by $190. For stepped care, annual costs would be $205 and $212 lower for those treated initially with labetalol. Labetalol therefore may be more cost effective than propranolol among black adults with mild to moderate hypertension.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Abengowe C. U. A double-blind comparison of acebutolol (Sectral) and propranolol (Inderal) in the treatment of hypertension in black Nigerian patients. J Int Med Res. 1985;13(2):116–121. doi: 10.1177/030006058501300207. [DOI] [PubMed] [Google Scholar]
- Bosman A. R., Goldberg B., McKechnie J. K., Offermeier J., Oosthuizen O. J. South African multicentre study of metoprolol and propranolol in essential hypertension. S Afr Med J. 1977 Jan 15;51(3):57–61. [PubMed] [Google Scholar]
- Flamenbaum W., Weber M. A., McMahon F. G., Materson B. J., Carr A. A., Poland M. Monotherapy with labetalol compared with propranolol. Differential effects by race. J Clin Hypertens. 1985 Mar;1(1):56–69. [PubMed] [Google Scholar]
- Goodman C., Rosendorff C., Coull A. Comparison of the antihypertensive effect of enalapril and propranolol in black South Africans. S Afr Med J. 1985 Apr 27;67(17):672–676. [PubMed] [Google Scholar]
- Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. Am J Med. 1980 Nov;69(5):725–732. doi: 10.1016/0002-9343(80)90438-6. [DOI] [PubMed] [Google Scholar]
- Heyman A., Karp H. R., Heyden S., Bartel A., Cassel J. C., Tyroler H. A., Hames C. G. Cerebrovascular disease in the biracial population of Evans County, Georgia. Arch Intern Med. 1971 Dec;128(6):949–955. [PubMed] [Google Scholar]
- Humphreys G. S., Delvin D. G. Ineffectiveness of propranolol in hypertensive Jamaicans. Br Med J. 1968 Jun 8;2(5605):601–603. doi: 10.1136/bmj.2.5605.601. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jennings K., Parsons V. A study of labetalol in patients of European, West Indian and West African origin. Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):773–775. [PubMed] [Google Scholar]
- Keil J. E., Loadholt C. B., Weinrich M. C., Sandifer S. H., Boyle E., Jr Incidence of coronary heart disease in blacks in Charleston, South Carolina. Am Heart J. 1984 Sep;108(3 Pt 2):779–786. doi: 10.1016/0002-8703(84)90671-9. [DOI] [PubMed] [Google Scholar]
- Michelson E. L., Frishman W. H., Lewis J. E., Edwards W. T., Flanigan W. J., Bloomfield S. S., Johnson B. F., Lucas C., Freis E. D., Finnerty F. A. Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension. Am J Med. 1983 Oct 17;75(4A):68–80. doi: 10.1016/0002-9343(83)90138-9. [DOI] [PubMed] [Google Scholar]
- Seedat Y. K., Reddy J. Propranolol in the South African non-white hypertensive patient. S Afr Med J. 1971 Mar 13;45(11):284–285. [PubMed] [Google Scholar]
- Shimizu Y., Kato H., Lin C. H., Kodama K., Peterson A. V., Prentice R. L. Relationship between longitudinal changes in blood pressure and stroke incidence. Stroke. 1984 Sep-Oct;15(5):839–846. doi: 10.1161/01.str.15.5.839. [DOI] [PubMed] [Google Scholar]
- Stamler J., Schoenberger J. A., Lindberg H. A., Shekelle R., Stoker J. M., Epstein M. B., Stamler R., DeBoer L., Restivo R., Gray D. Detection of susceptibility to coronary disease. Bull N Y Acad Med. 1969 Dec;45(12):1306–1325. [PMC free article] [PubMed] [Google Scholar]